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AbsTrACT
background germline pathogenic variants in SDHB/
SDHC/SDHD are the most frequent causes of inherited 
phaeochromocytomas/paragangliomas. insufficient 
information regarding penetrance and phenotypic 
variability hinders optimum management of mutation 
carriers. We estimate penetrance for symptomatic 
tumours and elucidate genotype–phenotype correlations 
in a large cohort of SDHB/SDHC/SDHD mutation carriers.
Methods a retrospective survey of 1832 individuals 
referred for genetic testing due to a personal or family 
history of phaeochromocytoma/paraganglioma. 876 
patients (401 previously reported) had a germline 
mutation in SDHB/SDHC/SDHD (n=673/43/160). tumour 
risks were correlated with in silico structural prediction 
analyses.
results tumour risks analysis provided novel 
penetrance estimates and genotype–phenotype 
correlations. in addition to tumour type susceptibility 
differences for individual genes, we confirmed that the 
SDHD:p.Pro81leu mutation has a distinct phenotype and 
identified increased age-related tumour risks with highly 
destabilising SDHB missense mutations. By Kaplan-Meier 
analysis, the penetrance (cumulative risk of clinically 
apparent tumours) in SDHB and (paternally inherited) 
SDHD mutation-positive non-probands (n=371/67 with 
detailed clinical information) by age 60 years was 21.8% 
(95% ci 15.2% to 27.9%) and 43.2% (95% ci 25.4% 
to 56.7%), respectively. risk of malignant disease at age 
60 years in non-proband SDHB mutation carriers was 
4.2%(95% ci 1.1% to 7.2%). With retrospective cohort 
analysis to adjust for ascertainment, cumulative tumour 
risks for SDHB mutation carriers at ages 60 years and 
80 years were 23.9% (95% ci 20.9% to 27.4%) and 
30.6% (95% ci 26.8% to 34.7%).
Conclusions Overall risks of clinically apparent tumours 
for SDHB mutation carriers are substantially lower 
than initially estimated and will improve counselling 
of affected families. Specific genotype–tumour risk 
associations provides a basis for novel investigative 
strategies into succinate dehydrogenase-related 
mechanisms of tumourigenesis and the development 
of personalised management for SDHB/SDHC/SDHD 
mutation carriers.
InTroduCTIon
The succinate dehydrogenase (SDH) enzyme 
complex comprises four subunits (A–D), localises 
to the inner mitochondrial membrane and catal-
yses the oxidation of succinate during the Krebs 
cycle. Three subunit genes (SDHB/SDHC/SDHD) 
are among the most important susceptibility genes 
for the neuroendocrine tumours head and neck 
paraganglioma (HNPGL) and phaeochromocytoma 
and paraganglioma (PPGL).1 2 HNPGLs are derived 
from parasympathetic-derived ganglia, whereas 
PPGLs are derived from sympathetic ganglia and 
usually secrete catecholamines. HNPGL and PPGL 
have a strong genetic basis, with approximately 
40% being associated with a germline mutation in 
one of at least 15 genes.3
Since the identification of the role of SDHB/
SDHC/SDHD in inherited PPGL/HNPGL at the 
start of this century,4–6 testing for germline muta-
tions in these genes has become part of standard 
medical practice. As testing became more wide-
spread, it was revealed that mutations in SDHC and 
SDHD were associated with a higher risk of HNPGL 
than PPGL, with the reverse for SDHB.7–10SDHB 
mutations are associated with a higher risk of malig-
nancy and renal carcinoma than mutations in other 
subunits.7 10 11 Initially, the penetrance of SDHB 
mutations was estimated at ~70%–80%, and inten-
sive surveillance programmes were recommended, 
but more recent estimates suggest the tumour risk 
is <50% in non-probands.7 12–14 The combination 
of malignancy risk with incomplete penetrance 
makes designing an optimal surveillance programme 
for asymptomatic SDHB mutation carriers diffi-
cult. More accurate predictions of life-time tumour 
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risks and identification of subgroups with higher or lower risks 
would enable the development of personalised management and 
surveillance strategies.
Previously we reported the mutation spectrum and genotype–
phenotype correlations in 358 patients with germline mutations 
in SDHB and SDHD.10 Here we report the results of analysis on 
an expanded cohort of germline SDHB/SDHC/SDHD mutation 
carriers and stratify missense mutations according to predicted 
effects on structure and function. We provide more accurate 
estimates of tumour-specific risks, confirm the mutation-spe-
cific phenotype of the SDHD p.Pro81Leu mutation and iden-
tify a novel candidate genotype–phenotype association of SDHB 
missense mutations with effects on SDHB protein stability.
MATerIAls And MeThods
Patient cohort
The study sample consisted of men and women referred for 
SDHB/SDHC/SDHD mutation analysis in National Health 
Service diagnostic laboratories for a personal or family history 
of PPGL/HNPGL. Carriers of pathogenic mutations in other 
genes were excluded from this study. Clinical information was 
collected via a standard pro forma (see online supplementary 
figure 1), or clinical records, for research studies or a service 
evaluation study. Non-probands (those tested after a SDHB/S-
DHC/SDHD mutation was detected in their relative) were 
included except those with maternally inherited SDHD muta-
tions who, because of a parent of origin effect, will have a 
tumour penetrance more similar to that of the general popula-
tion.15 One proband, described previously,16 had a maternally 
inherited SDHD mutation. Affected individuals were diag-
nosed by routine clinical investigations. The work described 
was performed in accordance with the Declaration of Helsinki. 
All participants gave informed consent for genetic testing. The 
service evaluation study was approved by Birmingham Women’s 
Hospital R&D Office. A subgroup of patients (n=401) have 
been described previously6 10 14 17–19 with 358 included in Rick-
etts et al.10 We refer to patients as having ‘detailed clinical infor-
mation’ if we have received a clinical information proforma or 
have access to their records to ascertain the presence or absence, 
and age of onset, of tumours. Patients without detailed clinical 
information were those for whom we had the genetic test report 
but insufficient extra information to include them in the pene-
trance analyses (they were censored at age zero). Clinical infor-
mation was collected at the time of genetic testing and prior to 
baseline biochemical and imaging screening of asymptomatic 
gene carriers.
Molecular genetic analysis
SDHB/SDHC/SDHD mutations were detected by Sanger 
sequencing, next-generation sequencing assay20 or multiplex 
ligation-dependent probe amplification (MLPA) analysis (SALSA 
MLPA Kit P226; MRC-Holland, Amsterdam, The Netherlands) 
(details available on request).
SDHB/SDHC/SDHD sequence variants were classified as 
pathogenic/benign/variants of uncertain significance (VUS) by 
the reporting diagnostic laboratory. As methods of variant classi-
fication were not uniform between laboratories, all classifications 
were compared with the ClinVar classification,21 where avail-
able. Where there was a disagreement between the local labo-
ratory classification and the ClinVar classification, the variant 
was described as VUS. This method was chosen to minimise the 
chance of underestimating penetrance of tumours because of 
inclusion of families without a true pathogenic variant. Tumour 
risks and genotype–phenotype correlations were calculated in 
individuals with variants considered to be pathogenic or likely 
pathogenic by the diagnostic laboratory (65 probands with a 
VUS were excluded from penetrance calculations).
In silico protein structure analysis
The DUET and mCSM-PPI scoring systems22–24 were used to 
predict the structural consequences of missense mutations on 
protein stability and protein–protein affinity, respectively, using 
the models of SDHB, SDHD and the succinate complex (see 
supplementary information).
statistical analysis
Tumour risks were estimated by Kaplan-Meier analysis (SDHB/
SDHD/SDHC). All statistical tests were performed using the 
programming language R unless otherwise stated.25 The ‘survfit’ 
function from the survival package was used for Kaplan-Meier 
survival analysis and penetrance calculations. The log-rank test 
was used to compare survival distributions between cohorts of 
different genotypes. To account for the non-random ascertain-
ment of study participants with respect to their disease status, 
separate penetrance estimation analyses were carried out, in 
which we modelled the retrospective likelihood of the observed 
mutation status conditional on the disease phenotypes26 
(online supplementary material). The analysis was carried out 
in the pedigree analysis software MENDEL.27 The retrospec-
tive cohort analysis was not used for SDHD, because it does 
not address the fact that the ascertainment of SDHD mutation 
carriers considered the parental origin of the mutation. The 
0.05 level of significance was used for all tests, with Bonferroni 
correction for multiple comparisons where stated. All tests were 
two sided.
resulTs
spectrum of sdhb/sdhC/sdhd mutations
Of 1832 patients referred for genetic testing due to a personal or 
family history of PPLG/HNPGL, 1093 were probands and 1227 
had detailed clinical information available. Eight hundred seven-
ty-six had a mutation in either SDHB (n=673, probands=275), 
SDHC (n=43, probands=26) or SDHD (n=160, probands=90) 
(see online supplementary figure 2).
Copy number abnormalities (CnAs)
Forty-five probands had MLPA-detected single/multiple exon 
deletions or duplications in SDHB (n=36), SDHC (n=6) or 
SDHD (n=3) (see online supplementary table 1). Three of 36 
SDHB probands with a CNA had a single or multiexon dupli-
cation. The proportion of SDHB CNAs that were whole gene 
deletions (5.6%), exon 1 deletions (49%) and exon 3 deletions 
(14%) was similar to that in other published cohorts,8 28 29 
except for cohorts from the Netherlands where exon 3 deletions 
predominate.30 31 We found 83% (5/6) of SDHC CNAs were 
exon 6 deletions, and all three SDHD CNAs in our series were 
exon 4 deletions.
Intragenic mutations
Three hundred and forty-four probands and 436 of their rela-
tives harboured an intragenic mutation in SDHB/SDHC/SDHD 
(table 1). Forty-five intragenic mutations in 134 probands were 
reported previously.10 The ratio of mutation classes among 
probands was similar to that reported previously10 (44% 
missense, 15% nonsense, 13% splice-site, 15% frameshift, 
0.5% inframe deletions and 12% large CNAs). There were a 
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Table 1 List of all intragenic mutations found in SDHB, SDHC and SDHD
Gene Mutation Amino acid change no. of probands loVd Id59 or reference
SDHB c.17_42dup26 p.Ala15ProfsX4 1 Jafri et al14
SDHB c.72+1G>A Splice 3 LOVD ID SDHB_00171
SDHB c.72+1G>C Splice 1 Ricketts et al10
SDHB c.72+1G>T Splice 36 LOVD ID SDHB_000065
SDHB c.79C>T p.Arg27X 7 LOVD ID SDHB_000006
SDHB c.88delC p.Gln30ArgfsX47 7 LOVD ID SDHB_000017
SDHB c.118A>G p.Lys40Glu 8 LOVD ID SDHB_000018
SDHB c.136C>T p.Arg46X 11 LOVD ID SDHB_000021
SDHB c.137G>A p.Arg46Gln 22 LOVD ID SDHB_000022
SDHB c.141G>A p.Trp47X 1 LOVD ID SDHB_000023
SDHB c.166_170delCCTCA p.Pro56TyrfsX5 2 LOVD ID SDHB_000025
SDHB c.268C>T p.Arg90X 8 LOVD ID SDHB_000001
SDHB c.282_283insCTTA p.Glu95LeufsX25 3 LOVD ID SDHB_000206
SDHB c.286+2T>A Splice 1 LOVD ID SDHB_000092
SDHB c.286G>A p.Gly96Ser 6 LOVD ID SDHB_000207
SDHB c.287–1G>C Splice 1 LOVD ID SDHB_000040
SDHB c.292T>C p.Cys98Arg 1 LOVD ID SDHB_000068
SDHB c.296G>A p.Gly99Asp 1 LOVD ID SDHB_000070
SDHB c.297delC p.Ser100LeufsX4 1 LOVD ID SDHB_000208
SDHB c.298T>C p.Ser100Pro 4 LOVD ID SDHB_000089
SDHB c.302G>A p.Cys101Tyr 1 LOVD ID SDHB_000041
SDHB c.311delAinsGG p.Asn104ArgfsX15 4 LOVD ID SDHB_000071
SDHB c.325_335del11 p.Asn109LeufsX6 1 LOVD ID SDHB_000209
SDHB c.338G>A p.Cys113Tyr 3 LOVD ID SDHB_000210
SDHB c.339_352del14 p.Cys113X 1 Not described
SDHB c.343C>T p.Arg115X 6 LOVD ID SDHB_000042
SDHB c.379dupA p.Ile127AsnfsX28 7 LOVD ID SDHB_000211
SDHB c.380T>A p.Ile127Asn 2 LOVD ID SDHB_000043
SDHB c.380T>G p.Ile127Ser 21 LOVD ID SDHB_000072
SDHB c.418G>T p.Val140Phe 3 LOVD ID SDHB_000095
SDHB c.423+1G>A Splice 3 LOVD ID SDHB_000047
SDHB c.445C>T p.Gln149X 1 Not described
SDHB c.502dupC p.Gln168ProfsX11 1 LOVD ID SDHB_000075
SDHB c.526G>T p.Glu176X 1 LOVD ID SDHB_000212
SDHB c.552C>G p.Tyr184X 1 Not described
SDHB c.567_568delTG p.Ala190LeufsX3 1 Not described
SDHB c.587G>A p.Cys196Tyr 7 LOVD ID SDHB_000054
SDHB c.590C>G p.Pro197Arg 11 LOVD ID SDHB_000002
SDHB c.591delC p.Ser198AlafsX22 1 LOVD ID SDHB_000003
SDHB c.600G>T p.Trp200Cys 17 LOVD ID SDHB_000098
SDHB c.642+1G>T Splice 1 Meyer-Rochow et al60
SDHB c.649C>T p.Arg217Cys 1 LOVD ID SDHB_000086
SDHB c.650G>T p.Arg217Leu 1 LOVD ID SDHB_000159
SDHB c.660dupT p.Asp221X 1 LOVD ID SDHB_000057
SDHB c.685_686ins13 p.Glu229AlafsX31 1 LOVD ID SDHB_000213
SDHB c.688C>G p.Arg230Gly 1 LOVD ID SDHB_000100
SDHB c.688C>T p.Arg230Cys 1 LOVD ID SDHB_000058
SDHB c.689G>A p.Arg230His 5 LOVD ID SDHB_000108
SDHB c.724C>T p.Arg242Cys 4 LOVD ID SDHB_000060
SDHB c.725G>A p.Arg242His 2 LOVD ID SDHB_000004
SDHB c.745_748dupTGCA p.Thr250MetfsX7 1 Jafri et al14
SDHC c.1A>T Start codon mutation 3 LOVD ID SDHD_000006
SDHC c.43C>T p.Arg15X 1 LOVD ID SDHC_000013
SDHC c.77+2dupT Splice 1 Buffet et al28
SDHC c.148C>T p.Arg50Cys 1 LOVD ID SDHC_000024
SDHC c.345dupA p.Ala116SerfsX2 1 Not described
SDHC c.378T>G p.Tyr126X 1 Not described
SDHC c.380A>G p.His127Arg 7 LOVD ID SDHC_000055
SDHC c.397C>T p.Arg133X 5 LOVD ID SDHC_000015
SDHD c.1A>G Start codon mutation 1 LOVD ID SDHD_000021
Continued
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number of recurrent mutations, for example, SDHB splice-site 
c.72+1G>T and SDHD missense c.242C>T (p.Pro81Leu) 
mutations accounted for 20% of probands, and the 10 most 
common mutations accounted for 48% (see online supplemen-
tary figure 3).
Clinical presentation
Of 297 probands with a SDHB/SDHC/SDHD mutation and 
detailed clinical information, the presenting features were 
predominantly PPGL and HNPGL, though the frequency varied 
by gene (see  online supplementary table 3). Three hundred and 
seventy-four of the 454 non-proband SDH mutation carriers 
with detailed clinical information were asymptomatic at testing.
Age-related tumour risks
Tumour risks were estimated by Kaplan-Meier analysis for all 
SDHB/SDHD/SDHC mutation carriers, probands only and 
non-probands only for SDHD non-proband carriers only those 
with paternally inherited mutations). For SDHB, retrospective 
cohort analysis was also performed using all samples combined 
(probands and non-probands), probands only and using non-pro-
bands only.
Kaplan-Meier analysis (and log-rank testing) of probands and 
non-probands (figure 1) revealed higher penetrance for symp-
tomatic tumours in SDHD than in SDHB mutation carriers 
(P=0.032), increased age-related risk of HNPGL in SDHD than 
SDHB mutation carriers (P<0.0001) and higher risk of PPGL 
in SDHB than SDHD (P=0.00019). SDHB carriers were more 
likely to develop malignant disease (P=0.0043). These findings 
remained significant when the previously reported 358 patients10 
were excluded from the analysis (data not shown).
In 34 SDHC mutation carriers with detailed clinical infor-
mation, 19 were clinically affected (15 HNPGL, 3 PPGL and 1 
had both HNPGL and PPGL). One patient with HNPGL had 
local spread and malignant features. Age-related risks of symp-
tomatic PPGL/HNPGL in SDHC were similar to that of SDHD. 
Compared with SDHB mutation carriers, SDHC carriers had 
a lower risk of PPGL (P=0.02 and P=0.06 before and after 
Bonferroni correction) and a higher risk of HNPGL (P<0.001 
after Bonferroni correction for three comparisons, log-rank test) 
(figure 1).
Overall tumour risks will be inflated by including both 
probands and non-probands (as probands always have the 
disease) so we re-estimated the cumulative risks in non-pro-
bands only. Using Kaplan-Meier analysis, the estimated risk 
of PPGL/HNPGL at age 60 years in SDHB, SDHD and SDHC 
mutation positive non-probands was 21.8% (95% CI 15.2% 
to 27.9%), 43.2% (95% CI 25.4% to 56.7%) and 25% (95% 
CI 0% to 57.0%), respectively. Nine non-probands (all 
SDHB) developed malignant disease, and the risk of malig-
nant disease at age 60 years in non-proband SDHB mutation 
carriers was 4.2% (95% CI 1.1% to 7.2%).
As expected, estimates of penetrance from the retrospec-
tive cohort analysis of a combined sample of probands and 
non-probands were lower than the above estimates from 
Kaplan-Meier analysis as the former method provides some 
adjustment for ascertainment bias. Under the retrospective 
cohort analysis, the predicted penetrance of PPGL/HNPGL 
in SDHB mutation carriers (probands and non-probands) by 
age 60 years and age 80 years was 23.9% (95% CI 20.9% 
to 27.4%) and 30.6% (95% CI 26.8% to 34.7%), respec-
tively (see figure 2), similar to the Kaplan-Meier estimates in 
non-probands.
Male SDHB mutation carriers have a higher age-related pene-
trance of PPGL/HNPGL (P=0.0034) and PPGL (P=0.0079), 
compared with women (see online supplementary figure 4), as 
calculated by Kaplan-Meier analysis and log-rank testing.
Gene Mutation Amino acid change no. of probands loVd Id59 or reference
SDHD c.14G>A p.Trp5X 2 LOVD ID SDHD_000026
SDHD c.33C>A p.Cys11X 1 LOVD ID SDHD_000027
SDHD c.36dupT p.Ala13CysfsX56 1 Not described
SDHD c.47_52+1del7 Splice 2 Not described
SDHD c.53dupC p.Leu19SerfsX50 1 Not described
SDHD c.57delG p.Leu20CysfsX66 1 LOVD ID SDHD_000080
SDHD c.64C>T p.Arg22X 2 LOVD ID SDHD_000012
SDHD c.91dupA p.Ile31AsnfsX38 1 Not described
SDHD c.94_95delTC p.Ala33IlefsX35 3 LOVD ID SDHD_000017
SDHD c.98_108del11 p.Ala33GlyfsX32 1 Not described
SDHD c.116_117insGATA p.Pro41TyrfsX29 1 Not described
SDHD c.144_145dupCA p.Ile49ThrfsX38 3 Not described
SDHD c.169+1G>A Splice 2 LOVD ID SDHD_000132
SDHD c.171delT p.Gly58AlafsX28 1 Not described
SDHD c.191_192delTC p.Leu64ProfsX4 4 LOVD ID SDHD_000013
SDHD c.205G>T p.Glu69X 1 Not described
SDHD c.242C>T p.Pro81Leu 39 LOVD ID SDHD_000003
SDHD c.242delC p.Pro81ArgfsX5 1 LOVD ID SDHD_000151
SDHD c.274G>T p.Asp92Tyr 3 LOVD ID SDHD_000004
SDHD c.276_278delCTA p.Tyr93del 2 LOVD ID SDHD_000038
SDHD c.296delT p.Leu99ProfsX36 9 LOVD ID SDHD_000040
SDHD c.325C>T p.Gln109X 2 LOVD ID SDHD_000046
SDHD c.341A>G p.Tyr114Cys 1 LOVD ID SDHD_000007
SDHD c.342T>A p.Tyr114X 2 LOVD ID SDHD_000083
The 15 mutations labelled as ‘Not described’ have, to the best of our knowledge, not been published elsewhere. 
Table 1  Continued
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other tumours
Previously,10 we reported 12/358 patients had renal tumours 
(11 SDHB and 1 SDHD), and the updated cohort contains an 
additional four cases (all SDHB). Of 751 patients with detailed 
clinical information (584 SDHB, 33 SDHC and 134 SDHD), 15 
(2.6%) SDHB carriers and 1 (0.7%) SDHD carrier had a renal 
tumour. The risk of developing a renal tumour by age 60 years in 
SDHB mutation carriers was 4.2% (95% CI 0.46% to 7.8%) by 
Kaplan-Meier analysis of non-probands, 4.71% (95% CI 1.65% 
to 7.7%) by Kaplan-Meier analysis of all SDHB mutation carriers 
and 5.6%/3.2% (male/female) by retrospective cohort analysis of 
all SDHB mutation carriers. No further thyroid tumours were 
found beyond the three described previously in SDHB mutation 
carriers,10 giving an estimated penetrance of thyroid tumours by 
age 60 years of 1.5% (95% CI 0.0% to 3.1%) (calculated by 
Kaplan-Meier analysis of all SDHB mutation carriers). Other 
rare tumours included: (A) SDHB carriers: pituitary adenoma, 
parathyroid adenoma and pulmonary carcinoid tumour; (B) 
SDHC: pituitary adenoma, gastrointestinal stromal tumour 
(GIST); and (C) SDHD: a pituitary tumour.
Genotype–phenotype correlations
Structural prediction analysis
SDHB and SDHD missense mutations were analysed using 
DUET24 to predict their effect on protein stability and 
Figure 1 Penetrance of for clinically diagnosed disease in proband and non-proband SDHB, SDHC and SDHD mutation carriers with 95% ci 
shaded. HnPgl, head and neck paraganglioma; PPgl, phaeochromocytoma and paraganglioma.
Figure 2 Penetrance of clinical disease in SDHB mutation carriers by age 60 years, as calculated by different statistical techniques and in different 
subpopulations. HnPgl,  head and neck paraganglioma; PPgl, phaeochromocytoma and paraganglioma; rcc, renal cell carcinoma.
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mCSM-PPI to predict their effect on succinate complex forma-
tion22 (table 2).
SDHB/SDHD variants with no or uncertain pathogenicity 
were predicted by DUET to have little effect on either protein 
stability and protein complex formation (average ΔΔG −0.15 
Kcal/mol) in contrast to disease associated mutations (average 
ΔΔG −1.41 Kcal/mol) (P<0.001 two-tailed t-test).
Of the 21 disease-associated SDHB missense mutations, 20 
are predicted to be destabilising, 16 are predicted to destabilise 
the complex and 4 (p.Cys98Arg, p.Cys101Tyr, p.Cys113Tyr and 
p.Cys196Tyr) are in metal coordinating cysteines. The most desta-
bilising SDHB missense mutation, p.Ile127Ser, affected an isole-
ucine residue buried deep in the protein with a strong network 
of intramolecular hydrophobic interactions32 (figure 3A). The 
three SDHB mutations not predicted to alter protein stability 
were all predicted to affect the coordination of an iron–sulphur 
cluster, either directly or by affecting neighbourhood residues 
(figure 3B).
Table 2 DUET score for all SDHB and SDHD missense mutations described in this cohort and for rare missense variants with no or unknown 
pathogenicity
Mutation Allele frequency mCsM stability (Kcal/mol) dueT (Kcal/mol) Predicted effect
SDHB – – – – 
p.Lys40Glu Unknown −1.741 −1.774 Destabilises protomer and complex
p.Arg46Gln 0.000008238 −0.997 −1.02 Destabilises protomer
p.Gly96Ser 0.000008381 −1.024 −1.09 Destabilises protomer; positive phi glycine; affect metal binding
p.Cys98Arg Unknown 0.217 0.316 Affect metal binding; destabilse complex
p.Gly99Asp Unknown −0.989 −1.216 Destabilises protomer and complex; affect metal binding
p.Ser100Pro Unknown −0.226 −0.368 Affect metal binding; destabilse complex
p.Cys101Tyr Unknown −1.06 −1.651 Destabilises protomer; affect metal binding
p.Cys113Tyr Unknown −0.974 −1.467 Destabilises protomer and complex; affect metal binding
p.Ile127Asn Unknown −3.088 −3.213 Destabilises protomer. Mildly destabilises complex
p.Ile127Ser Unknown −3.669 −3.856 Destabilises protomer
p.Val140Phe Unknown −1.233 −1.353 Destabilises protomer. Mildly destabilises complex
p.Cys196Tyr Unknown −1.407 −1.77 Destabilises protomer and complex; affect metal binding
p.Pro197Arg Unknown −0.954 −0.784 Destabilises protomer; mildly destabilises complex; affect metal binding; loss of 
conformational restraint
p.Trp200Cys Unknown −1.442 −1.205 Destabilises protomer and complex
p.Arg217Cys Unknown −1.916 −1.948 Destabilises protomer and complex
p.Arg217Leu Unknown −1.031 −0.879 Destabilises protomer and complex
p.Arg230Gly Unknown −1.848 −2.45 Destabilises protomer and complex
p.Arg230Cys 0.000008252 −1.739 −1.836 Destabilises protomer and complex
p.Arg230His Unknown −1.903 −2.133 Destabilises protomer
p.Arg242Cys Unknown −1.386 −1.619 Destabilises protomer; mildly destabilises complex; affect metal binding
p.Arg242His 0.00002471 −1.948 −2.035 Destabilises protomer; mildly destabilises complex; affect metal binding
SDHD – – – – 
p.Pro81Leu Unknown −0.297 0.036 Destabilising  transmembrane
p.Asp92Tyr Unknown −0.907 −0.868 Destabilising transmembrane
p.Tyr114Cys Unknown 0.236 0.388 Stabilising
Mutations with no or unknown pathogenicity 
Mutation Allele frequency mCsM dueT Predicted effect
SDHB – – – – 
p.Ala3Gly 0.00436 −0.28 −0.244 Neutral
p.Thr17Ala Unknown −0.943 −0.82 Destabilising
p.Cys22Ser 0.0001331 0.119 0.135 Neutral
p.Arg27Gly 0.00004183 −0.229 −0.208 Neutral
p.His57Arg 0.0007249 −0.238 0.011 Neutral
p.Ser100Phe Unknown −0.226 −0.368 Neutral
p.Ser163Pro 0.01254 −0.136 −0.03 Introduction of a conformational restraint
SDHD – – – – 
p.Gly12Ser 0.007268 −0.377 −0.134 Altered localisation
p.Arg17Leu Unknown 0.549 0.481 Mildly stabilising
p.Ile40Val 0.00003295 −0.461 −0.182 Neutral
p.Glu42Ala Unknown −0.255 −0.017 Neutral
p.His50Arg 0.006515 −0.4 −0.155 Altered localisation
p.Pro87His Unknown −0.571 −0.442 Neutral
p.His145Asn Unknown −0.055 0.018 Neutral
Allele frequencies are as reported in the ExAC database (Exome Aggregation Consortium, Cambridge, Massachusetts, USA), all ethnicities, accessed 17 June 201761
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Structure–phenotype correlations and mutation specific phenotypes
We confirmed our previous observation10 that the SDHD 
p.Pro81Leu phenotype is distinct from that of other 
SDHD mutation carriers, with a low PPGL risk (figure 4). 
Of 53 individuals with detailed clinical information, 15 
were asymptomatic, 37 had HNPGL (two metastatic) and 
1 had PPGL (described previously by Yeap et al).16 The 
p.Pro81Leu mutation is predicted to have a very mild effect 
on protein stability. Excluding the cases originally analysed 
by Ricketts et al10 to create a replication cohort confirmed 
the lower risk of PPGL in SDHD p.Pro81Leu mutation 
carriers versus other SDHD mutation carriers (P=0.031, 
data not shown).
There were no differences in age-related risks of PPGL/
HNPGL between missense and truncating variants (data not 
shown). However, there was a higher overall penetrance for 
clinical disease (all tumour risk) (P=0.0047) and PPGL risk 
(P=0.00024) in p.Ile127Ser mutation carriers (the missense 
mutation with the highest DUET score for predicted protein 
instability) compared with other missense mutations. 
Furthermore, using the surv_cutpoint() function in R, which 
is designed to use the maximally selected rank statistics from 
the ‘maxstat’ R package to find the optimum cutpoint for 
continuous variables, the PPGL/HNPGL and PPGL risks 
were significantly higher for those missense mutations 
with the most destabilising DUET scores (PPGL/HNPGL 
penetrance: P=0.0086; PPGL penetrance: P=0.00025). 
The significance of these differences was preserved when 
calculated for probands only (PPGL/HNPGL penetrance: 
P=0.021; PPGL penetrance: P=0.0051, see figure 5).
dIsCussIon
To our knowledge, this is the largest series of SDHB/SDH-
C/SDHD mutation carriers yet reported (see  online supplemen-
tary tables 2 and 4) and the previous largest cohort from Buffet 
et al28 (363 probands, 269 with SDHB/C/D mutations), which 
did not report genotype–phenotype correlations. Our large-scale 
comprehensive genotype–phenotype assessments uncovered a 
series of novel observations:
Figure 3 (a) the isoleucine reside at position 127 of SDHB is buried in the middle of the structure, making a network of strong intramolecular 
hydrophobic interactions. Mutation to serine would introduce a polar residue and disrupt all of these important contacts. (B) One of three iron–sulphur 
clusters in SDHB, coordinated by four cysteine residues. Four of these (cys98, cys101, cys113 and cys196) are mutated in our cohort.
Figure 4 Penetrance of clinical disease in proband and non-proband SDHD p.Pro81leu mutation carriers versus all other SDHD mutation carriers with 
95% ci marked. P values are for the log-rank test comparing the survival distributions of SDHD p.Pro81leu and all other SDHD mutation carriers. HnPgl,   
head and neck paraganglioma; PPgl, phaeochromocytoma and paraganglioma.
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Gene-specific and mutation-specific differences in penetrance 
and expression
We unequivocally confirmed that SDHD mutation carriers had a 
higher overall penetrance for symptomatic tumours and a higher 
risk of HNPGL compared with SDHB, whereas SDHB mutation 
carriers had a higher risk of malignancy and were significantly 
more likely to develop PPGL. We have confirmed the findings 
of Jochmanova et al33 that male SDHB mutation carriers are at 
higher risk of disease than females (calculated by Kaplan-Meier 
analysis and log-rank testing). The reason for this observation 
is not clear. Although it is possible that because asymptomatic 
female at risk relative might be more likely to come forward for 
predictive genetic testing than males we note that in our cohort, 
there were more male than female probands with SDHB muta-
tions (153 male, 110 female), and there were equal numbers of 
male and female non-probands with SDHB mutations (198 male, 
201 female). Of the unaffected at risk relatives without a muta-
tion (relatives of SDHB/D/C mutation carriers), 130 were female 
and just 103 were male.
The phenotype associated with SDHC mutations has not been 
well defined. Early reports described benign HNPGLs,5 34 35 
but more recent studies have also identified extra-adrenal para-
gangliomas and more invasive tumours. Bickmann et al36 and 
Bourdeau et al37 both describe SDHC p.Arg133X mutation 
carriers (a mutation that is also common in our cohort) presenting 
with extra-adrenal paragangliomas and HNPGLs, both benign 
and malignant. Our findings of SDHC mutation carriers with 
extra-adrenal paragangliomas, pheochromocytoma and a case 
of HNPGL with malignant features are consistent with similar 
tumour risks with SDHC and paternally inherited SDHD 
mutations (Lefebvre and Foulkes38 recommend similar tumour 
screening for SDHC and SDHD mutation carriers).
We replicated our previous finding that SDHD p.Pro81Leu 
mutation carriers manifest almost exclusively with HNPGL, 
while other SDHD mutation types predispose to both HNPGLs 
and PPGLs. From a clinical perspective, it can be proposed 
that SDHD p.Pro81Leu mutation carriers do not need inten-
sive imaging for PPGL. Although the risk of PPGL in SDHD 
p.Pro81Leu mutation carriers was not zero, the single patient 
with a phaeochromocytoma was highly unusual16 and was the 
only example of tumour development after maternal inheri-
tance of a SDHD mutation. Interestingly, all of the rare cases 
of tumours in individuals with maternally inherited SDHD 
mutations have been phaeochromocytomas and none have 
had a HNPGL.16 39 40SDHD has a key role in anchoring the 
SDH complex to the inner mitochondrial membrane, and a 
truncating SDHD mutation would inactivate the function of 
the entire SDH complex and be predicted to lead to disordered 
signalling in the hypoxic gene response pathway and to epigen-
etic abnormalities resulting from inhibition of enzymes such as 
prolyl-hydroxylases and ten-eleven translocation enzymes.41–44 
The SDHD p.Pro81Leu mutation is predicted not to cause 
protein instability but to interfere with ubiquinone metabolism/
electron transport by changing the folding of helix 1S and by 
destroying a ubiquinone binding site.10 45 The small risk of PPGL 
with the p.Pro81Leu mutations suggests that PPGL and HNPGL 
result from impairment of different aspects of the function of the 
SDH complex.
Our in silico analysis of the structural effects of SDHB missense 
mutations revealed a novel genotype–phenotype association in 
which the missense mutations predicted to have the greatest 
protein destabilising effects were associated with a higher 
penetrance and risk of PPGL. If these findings are confirmed, 
they could be used to stratify tumour surveillance programmes 
according to individual mutation risks. They could complement 
other methods, such as tumours studies and in vitro functional 
studies in human tissues or model organisms such as yeast,46 to 
elucidate the molecular mechanisms and clinical significance of 
the mutation.
other tumours
We also found a variety of rarer tumour types in individuals with 
SDHB/SDHC/SDHD mutations, including renal cell carcinoma 
(RCC), GIST, thyroid and pituitary tumours.7 10 47–51 The highest 
risk for RCC is in SDHB mutation carriers (though they can 
Figure 5 Penetrance of clinical disease in SDHB missense mutation carrier probands, split by with more stabilising (more negative) and less destabilising 
(less negative) DUet scores. the maximally selected rank statistics from the ‘maxstat’ r package was used to find the optimum cutpoint for DUet score, and 
the number of probands in the DUet score groups for each analysis is displayed in ‘number at risk’ tables below each plot. the optimum cutpoints for DUet 
score were −1.21 for PPgl risk and for PPgl/HnPgl risk, −0.88 for HnPgl risk and −1.02 for malignancy risk. HnPgl,   head and neck paraganglioma; 
PPgl, phaeochromocytoma and paraganglioma.
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occur in SDHD and SDHC mutation carriers), and we estimated 
the risk of RCC by age 60 years in SDHB carriers is 4.7% (95% 
CI 1.6% to 7.7%) by Kaplan-Meier analysis of probands and 
non-probands and 5.63%/3.18% (male/female risk) by retro-
spective cohort analysis.
Although the risk of renal tumours is smaller than for PPGL, 
if abdominal imaging is being performed for PPGL, it is straight-
forward to incorporate renal imaging. Our results suggest that 
thyroid imaging is not indicated if asymptomatic.
Penetrance in non-probands
Accurate knowledge of the natural history of a disease is 
required for optimum management. For rare diseases, there 
may be limited numbers of affected individuals, and ascertain-
ment bias in research studies can result in over-representation of 
extreme phenotypes with overestimation of disease risks. Inter-
estingly, with wider application of SDHB/C/D genetic testing, 
penetrance estimates for SDHB mutation carriers have declined. 
Original methods used Kaplan-Meier analysis of both probands 
and non-probands and produced penetrance estimates such as 
75% by age 50 years,7~55% by age 50 years12 and 50% by 
age 50 years.10 Subsequently, analyses have been published that 
have controlled for ascertainment bias by excluding probands, 
producing estimates more like 20% by age 50 years.14 33 An alter-
native approach has been to study a single large family so that 
the majority of patients analysed are non-probands, producing 
penetrance estimates of 35% by age 40 years52 and 26% by age 
48.53 More recently, the use of maximum likelihood methods to 
control for ascertainment bias has resulted in estimates of pene-
trance as low as 13%,13 9%54 and 21%55 at age 50 years.
The above cohorts have ranged in size from 15 to 344 SDHB 
mutation carriers. To better understand the prognosis for in indi-
viduals undergoing predictive testing, we tested a large (n=584 
with detailed clinical information) cohort of SDHB mutation 
carriers, adjusting for ascertainment bias using two approaches. 
We estimated overall clinical penetrance and tumour-specific 
risks by Kaplan-Meier analysis after excluding probands and 
compared the estimates with those obtained by retrospective 
cohort analysis in SDHB mutation carriers. We estimated clin-
ical disease penetrance in non-proband SDHB mutation carriers 
at 50 years, 60 years and 80 years to be 16%, 22% and 44%, 
respectively, and these were similar with the retrospective cohort 
analysis estimates: cumulative risk of 24% for PPLG/HNPGL by 
age 60 years and 31% by age 80 years. One limitation to our 
analysis was that the unavailability of pedigree structures that 
would have allowed us to look for potential parent-of-origin 
effects and to fully adjust for ascertainment.
The recent demonstrations of lower tumour risks raise 
important questions regarding follow-up for asymptomatic 
SDHB mutation carriers. Blood/urine biochemical analysis to 
detect metanephrines is inexpensive, but the risk of non-secre-
tory and malignant PPGL/HNPGL and renal and GIST tumours 
would argue for regular imaging. The Endocrine Society guide-
lines56 recommend annual biochemistry with urine or plasma 
metanephrines and 2 yearly cross-sectional imaging using either 
CT/MRI of skull base, neck, thorax abdomen and pelvis. It 
should be noted that the our tumour risk estimates are for clin-
ically apparent disease and are censored at the time of genetic 
testing. Subsequently, asymptomatic mutation carriers will 
have undergone biochemical and radiological surveillance and, 
though this information was not available, some may have been 
found to have an asymptomatic tumour. Thus, in a study of 30 
SDHx mutation carriers,57 a tumour was detected in one patient 
after 1 year follow-up from normal baseline imaging. Tufton 
et al58 describe a cohort of 65 asymptomatic SDHB mutation 
carriers undergoing surveillance by MRI. They found that 25% 
of these patients had a likely SDH-related tumour identified 
after baseline imaging or after a further 2–6 years of screening. 
The penetrance estimates for clinically apparent tumours in our 
study will be lower than those estimated in studies where patients 
have completed comprehensive screening and follow-up but 
are comparable with those from other large cohort studies and 
are consistent with more recent, although smaller, studies (see 
above) that have concluded that SDHB mutations are not asso-
ciated with a high lifetime risk for clinically apparent tumours. 
Although the non-inclusion of asymptomatic screen-detected 
lesions might be viewed as a limitation of the study design, it 
does avoid the uncertainties regarding whether asymptomatic 
tumours would become symptomatic, and the risk estimates 
for clinically apparent tumours are highly relevant to patients 
wishing to know their lifetime risks of having a symptomatic 
tumour.
In the light of the robust data from this and other studies 
demonstrating lower than previously estimated tumour risks in 
SDHB non-proband mutation carriers, there is a pressing need 
to continue to systematically collect data on the outcome of 
surveillance programmes. It is also highly relevant to develop 
strategies to enable patient stratification (eg, individuals at high 
risk because of specific mutations or family history/genetic modi-
fiers) and to enable non-invasive early detection of tumours.
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